MannKind Corporation Common Stock (MNKD) Stock
Key stats
- Market cap
- $1.35B
- Price / Earnings ratio
- -18.2x
- EPS (TTM)
- -$0.23
- Volume
- Loading
- 52-week high
- $6.51
- 52-week low
- $2.23
Source: third-party data provider, as of November 13, 2026
Compare with MNKD
Recent news

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth
MNKD

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MNKD

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
MNKD

MannKind Q2 Earnings Call Highlights
MannKind Q2 Earnings Call Highlights
MNKD
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 69.58
- MACD 12/26/9
- 0.18
- EMA 9 of MACD
- 0.08
- MACD histogram
- 0.11
- SMA 50
- $3.57
- Price above SMA 50
- EMA 50
- $3.63
- Price above EMA 50
- SMA 200
- $3.66
- Price above SMA 200
- EMA 200
- $3.93
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth
MannKind Advances Inhaled IPF Drug to Global Phase 2, Eyes FUROSCIX Growth
MNKD

MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum
MNKD

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH
MNKD

MannKind Q2 Earnings Call Highlights
MannKind Q2 Earnings Call Highlights
MNKD

Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics
MNKD

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates
MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates
MNKD

MannKind's Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway
MannKind's Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway
MNKD

MannKind injection helps heart failure patients avoid ER infusions
MannKind injection helps heart failure patients avoid ER infusions
MNKD

MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost
MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost
MNKD

MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE
MNKD
News tone: automated (AI) classification of the article's content, not a price prediction.
About MannKind Corporation Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Michael E. Castagna Pharm.D. | CEO & Director | 1976 |
| Mr. Christopher B. Prentiss M.B.A. | Chief Financial Officer | 1975 |
| Dr. David B. Thomson J.D., Ph.D. | Executive VP, General Counsel & Secretary | 1967 |
| Dr. Stuart A. Tross Ph.D. | Chief People & Workplace Officer | 1967 |
| Mr. Dominic Marasco R.Ph. | President of Endocrine Business Unit | 1972 |
| Mr. Sanjay Singh M.B.A. | Executive Vice President of Technical Operations | 1966 |
| Dr. Ajay Ahuja M.B.A., M.D. | Executive VP & Chief Medical Officer | 1970 |
| Dr. Wassim Fares M.D., M.Sc. | Senior VP and Therapeutic Area Head of Respiratory & (interim) Cariorenal | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 69.58
- MACD 12/26/9
- 0.18
- EMA 9 of MACD
- 0.08
- MACD histogram
- 0.11
- SMA 50
- $3.57
- Price above SMA 50
- EMA 50
- $3.63
- Price above EMA 50
- SMA 200
- $3.66
- Price above SMA 200
- EMA 200
- $3.93
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $5.00
- Average
- $7.50
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.3 | +1.2 | ||||||||||
| 2022 | -16.2 | -30.7 | +33.8 | -19.3 | +27.4 | -8.4 | -13.3 | +2.0 | -22.4 | +9.4 | +34.9 | +13.1 |
| 2023 | +5.0 | +0.2 | -15.1 | -6.8 | +17.2 | -9.2 | +14.8 | +2.7 | -10.8 | +6.5 | -10.2 | -3.4 |
| 2024 | -14.8 | +20.5 | +0.7 | -5.3 | +7.6 | +11.3 | +13.2 | +12.8 | +3.5 | +12.9 | -5.4 | -2.4 |
| 2025 | -12.3 | -4.1 | -1.9 | +1.8 | -16.2 | -12.8 | +5.6 | +22.4 | -6.4 | +3.9 | -2.4 | +4.4 |
| 2026 | +3.2 | -45.4 | -19.4 | +11.4 | +32.7 | +20.7 | -3.5 | +5.5 | -2.0 | -11.4 | +14.8 |



